Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. (TPST) is a biotechnology company focused on the development of small molecule therapeutics that modulate anti-tumor immunity pathways.
Tempest's mission is to pioneer novel treatments for cancer by leveraging a balanced and deep pipeline of small molecule therapeutics. These therapeutics are designed to modulate distinct immune response pathways that are crucial for mounting an effective anti-tumor response. Developed by Inception Sciences, a Versant Ventures-affiliated drug discovery engine, the company’s pipeline includes first-in-class and best-in-class molecules.
The company’s leading product candidates, TPST-1120 and TPST-1495, are in the clinical stage. TPST-1120 aims to inhibit its target to promote anti-tumor immunity, while TPST-1495 is designed to activate tumor-specific immune responses. These candidates are developed to address significant unmet medical needs across a range of cancers.
Tempest Therapeutics has assembled a highly experienced team of drug developers specializing in small molecules and immuno-oncology. This team is dedicated to advancing these programs through clinical trials and eventually to market. The company's robust research and development efforts are backed by a syndicate of leading venture capital firms based in the United States and China, providing strong financial support and strategic guidance.
Recent achievements for Tempest Therapeutics include the initiation and progress of randomized clinical trials, showcasing the company’s commitment to evidence-based development and regulatory approval. With a focus on innovation and patient outcomes, Tempest Therapeutics is well-positioned to make significant contributions to the field of oncology.
For more detailed information on the company’s latest updates, news, and financial performance, you can contact Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.
Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of an abstract for the 2023 ASCO Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The abstract focuses on TPST-1495, an EP2/EP4 prostaglandin receptor dual antagonist.
Presentation Details:
- Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
- Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
- Session Date and Time: June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
- Abstract Number: 3107
The abstract will be released on May 25, 2023, at 5:00 p.m. ET on the ASCO website.
Tempest Therapeutics, Inc. (Nasdaq: TPST) recently presented new data from its TPST-1120 and TREX1 programs at the 2023 American Association for Cancer Research Annual Meeting. The findings from TPST-1120, an oral PPAR⍺ antagonist, highlighted biomarker changes linked to drug exposure and response levels in patients undergoing treatment in a Phase 1 trial. Additionally, the TREX1 inhibitor program showcased novel human TREX1 enzyme structures, paving the way for potent inhibitors targeting the STING pathway. The company aims to advance TPST-1120 through multiple oncology indications and initiate human trials for the TREX1 inhibitors. Initial results from ongoing trials are expected soon, indicating promising possibilities for future cancer therapies.
Tempest Therapeutics, Inc. (TPST) reported significant clinical progress in 2022, highlighted by the completion of a Phase 1 study for TPST-1120, indicating a 30% objective response rate in patients unresponsive to traditional therapies. The randomization study in collaboration with Roche for first-line hepatocellular carcinoma (HCC) patients is fully enrolled, with data expected in mid-2023. Financially, Tempest saw a decline in cash reserves to $31.2 million and a net loss of $35.7 million for the year. However, the company anticipates adequate funding through Q2 2024, with ongoing developments in TPST-1495 and a promising TREX1 inhibitor program.
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced a poster presentation by Dr. Nathan Standifer at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Meeting from March 15-17 in Denver, CO, and online. The presentation will detail biomarker findings from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist. Key data indicate a link between clinical benefits and changes in fatty acid oxidation and gene expression. The presentation is scheduled for March 16, 2023, from 6:00 to 7:30 p.m. MT, and carries the abstract number 78. Tempest Therapeutics is focused on developing innovative oncology therapeutics that target various tumors.
FAQ
What is the current stock price of Tempest Therapeutics (TPST)?
What is the market cap of Tempest Therapeutics (TPST)?
What does Tempest Therapeutics, Inc. do?
What are Tempest Therapeutics' main product candidates?
Who developed Tempest Therapeutics' molecules?
What makes Tempest Therapeutics' pipeline unique?
Who are the key contacts for investor and media inquiries?
What type of cancers does Tempest Therapeutics target?
What is the core mission of Tempest Therapeutics?
What recent achievements has Tempest Therapeutics made?
Who supports Tempest Therapeutics financially?
How can I get the latest updates on Tempest Therapeutics?
